On July, 18 Analysts See $0.21 EPS for Swedish Orphan Biovitrum AB (publ)

June 27, 2018 - By Joseph March

Swedish Orphan Biovitrum AB (OTCMKTS:publ) Corporate Logo

On July, 18 is expected Swedish Orphan Biovitrum AB (OTCMKTS:publ)’s earnings report, Faxor reports. If reported the P/E will be 25.65 with $57.46M profit. Last quarter $0.24 EPS was reported. Analysts forecasts -12.50 % negative EPS growth this quarter. The stock decreased 2.36% or $0.52 during the last trading session, reaching $21.55.Swedish Orphan Biovitrum AB is after having 0.00% since June 27, 2017. publ has 965 volume or 315.95% up from normal. publ underperformed by 12.57% the S&P 500.

Swedish Orphan Biovitrum AB , an integrated biopharmaceutical company, researches, develops, makes, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetics and metabolism diseases primarily in Sweden and internationally.The company has $5.90 billion market cap. The Company’s core products include Kineret for the treatment of rheumatoid arthritis and neonatal-onset multisystem inflammatory disease; Orfadin for the treatment of hereditary tyrosinaemia type 1 genetic disorder; and Xiapex for the treatment of Dupuytren's contracture and Peyronie's disease.The P/E ratio is 35.5. The firm also offers Elocta and Alprolix for the treatment of haemophilia; and Ammonaps, Ammonul, and Ravicti for use in the genetics and metabolism diseases.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: